Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...
Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback